20-hydroxy-5,8,11,14-eicosatetraenoic acid and angiotensin ii, des-phe(8)-

20-hydroxy-5,8,11,14-eicosatetraenoic acid has been researched along with angiotensin ii, des-phe(8)- in 1 studies

Compound Research Comparison

Studies (20-hydroxy-5,8,11,14-eicosatetraenoic acid)	Trials (20-hydroxy-5,8,11,14-eicosatetraenoic acid)	Recent Studies (post-2010) (20-hydroxy-5,8,11,14-eicosatetraenoic acid)	Studies (angiotensin ii, des-phe(8)-)	Trials (angiotensin ii, des-phe(8)-)	Recent Studies (post-2010) (angiotensin ii, des-phe(8)-)
640	13	233	1,533	21	995

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Carroll, MA; Chander, PN; Kang, Y; Stier, CT	1

Other Studies

1 other study(ies) available for 20-hydroxy-5,8,11,14-eicosatetraenoic acid and angiotensin ii, des-phe(8)-

Article	Year
Azilsartan is associated with increased circulating angiotensin-(1-7) levels and reduced renovascular 20-HETE levels. American journal of hypertension, 2015, Volume: 28, Issue:5 Topics: Angiotensin I; Animals; Benzimidazoles; Blood Pressure; Disease Models, Animal; Hydroxyeicosatetraenoic Acids; Hypertension; Hypertension, Renovascular; Male; Oxadiazoles; Peptide Fragments; Rats; Rats, Sprague-Dawley; Vasoconstriction	2015

Article

Year

Azilsartan is associated with increased circulating angiotensin-(1-7) levels and reduced renovascular 20-HETE levels.

American journal of hypertension, 2015, Volume: 28, Issue:5

Topics: Angiotensin I; Animals; Benzimidazoles; Blood Pressure; Disease Models, Animal; Hydroxyeicosatetraenoic Acids; Hypertension; Hypertension, Renovascular; Male; Oxadiazoles; Peptide Fragments; Rats; Rats, Sprague-Dawley; Vasoconstriction

2015